Impact of plerixafor use in the mobilization of blood grafts for autologous hematopoietic cell transplantation

被引:4
作者
Jantunen, Esa [1 ,2 ]
Turunen, Antti [2 ]
Varmavuo, Ville [3 ]
Partanen, Anu [2 ]
机构
[1] Univ Eastern Finland, Inst Clin Med, Kuopio, Finland
[2] Kuopio Univ Hosp, Dept Med, Kuopio, Finland
[3] Kymenlaakso Cent Hosp, Dept Med, Kotka, Finland
关键词
autologous hematopoietic cell transplantation; CD34(+) cell mobilization; graft cellular composition; lymphoma; myeloma; outcome; plerixafor; COLONY-STIMULATING FACTOR; NON-HODGKINS-LYMPHOMA; PLUS G-CSF; STEM-CELL; MULTIPLE-MYELOMA; PROGENITOR CELLS; RECEPTOR CXCR4; CD34(+) CELLS; RISK-FACTORS; AMD3100;
D O I
10.1111/trf.17755
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Plerixafor (PLER), a reversible antagonist of the CXC chemokine receptor type 4, has been in clinical use for mobilization of blood grafts for autologous hematopoietic cell transplantation (AHCT) for about 15 years. Initially PLER was investigated in placebo-controlled trials with the granulocyte colony-stimulating factor (G-CSF) filgrastim. It has also been used in combination with chemotherapy plus G-CSF in patients who had failed a previous mobilization attempt or appeared to mobilize poorly with current mobilization (preemptive use). This review summarizes what is known regarding addition of PLER to standard mobilization regimens. PLER increases mobilization of CD34(+) cells, decreases the number of apheresis sessions needed to achieve collection targets and increases the proportion of patients who can proceed to AHCT. It appears also to increase the amount of various lymphocyte subsets in the grafts collected. In general, hematologic recovery after AHCT has been comparable to patients mobilized without PLER, although slower platelet recovery has been observed in some studies of patients who mobilize poorly. In phase III studies, long-term outcome has been comparable to patients mobilized without PLER. This also appears to be the case in patients receiving plerixafor for poor or suboptimal mobilization of CD34(+) cells. In practice, PLER is safe and has not been shown to increase tumor cell mobilization.
引用
收藏
页码:742 / 750
页数:9
相关论文
共 50 条
  • [21] Plerixafor for autologous CD34(+) cell mobilization
    Salman, Huda
    Lazarus, Hillard M.
    CORE EVIDENCE, 2011, 6 : 23 - 29
  • [22] Optimized peripheral blood progenitor cell mobilization for autologous hematopoietic cell transplantation in children with high-risk and refractory malignancies
    Furlong, Eliska
    Jensen, Jesper
    Woodard, Mark
    Griffiths, Katherine
    Knight, Geoff
    Sturm, Marian
    Kerr, Fiona
    Gough, Hazel
    Bear, Natasha
    Carter, Tina L.
    Cole, Catherine H.
    Kotecha, Rishi S.
    Ramachandran, Shanti
    PEDIATRIC TRANSPLANTATION, 2020, 24 (01)
  • [23] Novel strategies for blood stem cell mobilization: special focus on plerixafor
    Jantunen, Esa
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2011, 11 (09) : 1241 - 1248
  • [24] Plerixafor-based mobilization and mononuclear cell counts in graft increased the risk of engraftment syndrome after autologous hematopoietic stem cell transplantation
    Cao, Le-Qing
    Wen, Qi
    Liu, Bo-Ning
    Zhao, Zhen-Yu
    Zhang, Xiao-Hui
    Xu, Lan-Ping
    Chen, Huan
    Wang, Yu
    Yu, Lu
    Wang, Feng-Rong
    Huang, Xiao-Jun
    Mo, Xiao-Dong
    BLOOD SCIENCE, 2024, 6 (03): : e00190
  • [25] Pharmacoeconomic impact of up-front use of plerixafor for autologous stem cell mobilization in patients with multiple myeloma
    Kim, Sara S.
    Renteria, Anne S.
    Steinberg, Amir
    Banoff, Karen
    Isola, Luis
    CYTOTHERAPY, 2014, 16 (11) : 1584 - 1589
  • [26] Hematopoietic Progenitor Cell Mobilization for Autologous Stem Cell Transplantation in Multiple Myeloma in Contemporary Era
    Arora, Satyam
    Majhail, Navneet S.
    Liu, Hien
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (04) : 200 - 205
  • [27] The evolving role of plerixafor in hematopoietic progenitor cell mobilization
    Tanhehco, Yvette C.
    Vogl, Dan T.
    Stadtmauer, Edward A.
    O'Doherty, Una
    TRANSFUSION, 2013, 53 (10) : 2314 - 2326
  • [28] Use of Plerixafor for Stem Cell Mobilization in the Setting of Autologous and Allogeneic Stem Cell Transplantations: An Update
    Bilgin, Yavuz M.
    JOURNAL OF BLOOD MEDICINE, 2021, 12 : 403 - 412
  • [29] Development and validation of a decision-making algorithm to guide the use of plerixafor for autologous hematopoietic stem cell mobilization
    L J Costa
    E T Alexander
    K R Hogan
    C Schaub
    T V Fouts
    R K Stuart
    Bone Marrow Transplantation, 2011, 46 : 64 - 69
  • [30] Assessing the charges associated with hematopoietic stem cell mobilization and remobilization in patients with lymphoma and multiple myeloma undergoing autologous hematopoietic peripheral blood stem cell transplantation
    Hosing, Chitra
    Smith, Veronica
    Rhodes, Beverly
    Walters, Kent
    Thompson, Richmond
    Qazilbash, Muzaffar
    Khouri, Issa
    de Lima, Marcos
    Balzer, Richard J.
    McMannis, John
    Champlin, Richard
    Giralt, Sergio
    Popat, Uday
    TRANSFUSION, 2011, 51 (06) : 1300 - 1313